Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited

Hepatology

Volumn 36, Issue 3, 2002, Pages 525-531

  Paumgartner, Gustav ^a   Beuers, Ulrich ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; URSODEOXYCHOLIC ACID;

ADULT; ANIMAL CELL; ANIMAL MODEL; CHILD; CHOLESTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOTOXICITY; DOUBLE BLIND PROCEDURE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS; MOUSE; MULTICENTER STUDY; NONHUMAN; PARENTERAL NUTRITION; PREGNANCY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW;

EID: 0036725044     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36088     Document Type: Article

References (55)

1. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders.'
2. Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications
3. Ursodeoxycholic acid in the Ursidae: Biliary bile acids of bears, pandas, and related carnivores
4. Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trial
5. Pharmacology of ursodeoxycholic acid, an enterohepatic drug
6. Molecular aspects of membrane stabilization by ursodeoxycholate
7. Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: Implications for bile salt toxicity and cytoprotection
8. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene
9. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis
10. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
11. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial
12. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial
13. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period
14. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha
15. ++ mechanisms defective in cholestasis
16. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes
17. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver
18. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat
19. Kinetics of hepatic bile acid handling in cholestatic liver disease: Effect of ursodeoxycholic acid
20. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
21. Ursodiol for primary sclerosing cholangitis
22. Serum bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid therapy
23. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver
24. Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats
25. Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver
26. Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver
27. 2+ and activates phosphorylase a in isolated hepatocytes
28. Hepatocellular protein kinase C activation by bile acids: Implications for regulation of cholesterol 7 alpha-hydroxylase
29. Characterization of the mouse bile salt export pump overexpressed in the baculovirus system
30. Functional characterization of the phosphorylation of the bile salt export pump by protein kinase C
31. Modulation of protein kinase C by taurolithocholic acid in isolated rat hepatocytes
32. 2+ signals in isolated rat hepatocytes
33. Stimulation of ATP secretion in the liver by therapeutic bile acids
34. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis
35. Assessment of biliary bicarbonate secretion in humans by positron emission tomography
36. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas
37. Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes
38. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mtiochondrial transmembrane potential and reactive oxygen species production
39. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes
40. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid
41. Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells
42. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis
43. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis
44. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis
45. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A meta-analysis
46. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis
47. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: Outcome after endoscopic treatment
48. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: A randomized, double-blind study controlled with placebo
49. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: Effects on primary bile acids in babies and mothers
50. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: A doubleblind multicenter trial
51. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease
52. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis- related cholestatic liver disease. Results of a randomized study with 1-year follow-up
53. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis
54. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial
55. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: Evidence for involvement of cytochrome p450 3A4